Connect your AI

Kymera Therapeutics KYMR AFS Securities

AFS Securities at other companies

IncyteINCY

——

ExelixisEXEL

——

Other financials

Income statement

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kymera Therapeutics's AFS securities?: Kymera Therapeutics (KYMR) reported AFS securities of $894.72M in Q1 2026.
How has Kymera Therapeutics's AFS securities changed year-over-year?: Kymera Therapeutics's AFS securities increased by 186.5% year-over-year, from $312.34M to $894.72M.
What is the long-term trend for Kymera Therapeutics's AFS securities?: Over 5 years (2020 to 2025), Kymera Therapeutics's AFS securities has grown at a 36.5% compound annual growth rate (CAGR), from $162.53M to $771.16M.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.